New trial
Phase 4 TIVDAK tissue factor–directed antibody-drug conjugate ocular safety trial
- Trial ID
- NCT06952660 on ClinicalTrials.gov
- Cancer type
- Cervical Cancer
- Stage of research
- Exploratory
- Location
- 3 Locations
- Published in
- New in Oncology - July 3, 2025
This study by Pfizer evaluates ocular side effects in patients with recurrent/metastatic cervical cancer post-chemotherapy. Eligible participants have no active eye issues and are TIVDAK-naïve, with scheduled eye exams before treatment, during, and after every three-week infusion.
More in cervical and other gynecologic cancers
-
Trial result · Sep 24, 2026
Pembrolizumab (PD-1) + Chemotherapy Sustains 5-Year OS Benefit in 1L Advanced Cervical Cancer -
New trial · Aug 13, 2026 · NCT07672782
Phase 2 tisotumab vedotin (tissue factor–targeted) MMAE ADC in recurrent/metastatic vulvar SCC. -
Trial result · Jul 16, 2026 · NCT03750539
Hypofractionated pelvic RT (37.5Gy/15fx) + weekly cisplatin shows similar pCR vs standard 50Gy/25fx in LACC surgery cohort -
Trial result · Jul 16, 2026 · NCT06265727
CRB-701 (SYS6002) Nectin-4–targeted MMAE ADC shows early ~38% unconfirmed ORR in R/M cervical cancer -
Trial result · Jul 8, 2026 · NCT06288360
Camrelizumab (PD-1) + cisplatin/nab-paclitaxel hits 100% ORR and 30% pCR in PD-L1–negative LACC